BICO INC/PA
8-K, 2000-09-01
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Previous: SBL FUND, N-30D, 2000-09-01
Next: INTERMOUNTAIN INDUSTRIES INC /ID, SC 13E3, 2000-09-01






             SECURITIES AND EXCHANGE COMMISSION

                   Washington, D.C.  20549

                          FORM 8-K

                       CURRENT REPORT

           Pursuant to Section 13 or 15(d) of the
               Securities Exchange Act of 1934

                     ___________________



 Date of Report (Date of earliest event reported) August 29, 2000
                         BICO, INC.
   (Exact name of registrant as specified in its charter)


   Pennsylvania                 0-10822                 25-1229323
(State of other jurisdiction  (Commission File Number) (IRS Employer
  of incorporation)                                   Identification No.)


       2275 Swallow Hill Road, Bldg. 2500, Pittsburgh,
                     Pennsylvania 15220
            (Address of principal executive offices)
                         (Zip Code)


Registrant's telephone number, including area code (412) 429-0673




      _________________________________________________________
               (Former name or former address,
                if changes since last report.)









Item 1.   Change in Control of Registrant.
          Not applicable.

Item 2.   Acquisition or Disposition of Assets.
          Not applicable.

Item 3.   Bankruptcy or Receivership.
          Not applicable.

Item 4.   Changes in Registrant's Certifying Accountant
          Not applicable.

Item 5.   Other Events.

          BICO,  Inc. subsidiary, ViaCirQ, Inc., a leading
          developer of extracorporeal hyperthermia medical
          devices, announced today that it has entered into
          a three-year agreement with North Carolina Baptist
          Hospitals, Incorporated to provide Wake Forest
          University Baptist Medical Center with the
          ThermoChem-HT  System and disposable ThermoChem-HT
          System packs for all intraperitoneal hyperthermia
          procedures.

Item 6.   Resignation of Registrant's Directors.
          Not Applicable

Item 7.   Financial Statement, Pro Forma Financial Information and Exhibits.

          (a)  Financial Statements and Businesses Acquired - Not Applicable.
          (b)  Pro Forma Financial Information - Not Applicable.
          (c)  Exhibits - Press Release.

                         SIGNATURES

      Pursuant to the requirement of the Securities Exchange
Act  of 1934, the Registrant has duly caused this Report  to
be  signed  on  its behalf by the undersigned hereunto  duly
authorized.

                                   BICO, INC.

                                   by  /s/   Fred E. Cooper
                                             Fred E. Cooper, CEO
DATED:  August  29, 2000




          BICO SUBSIDIARY, VIACIRQ, INC., RECEIVES
              CONTRACT FOR THERMOCHEM-HT SYSTEM


     Pittsburgh,  PA  -  August  29,  2000  -   BICO,   Inc.
(OTCBB:BICO) subsidiary, ViaCirQ, Inc., a leading  developer
of  extracorporeal  hyperthermia medical devices,  announced
today  that it has entered into a three-year agreement  with
North  Carolina Baptist Hospitals, Incorporated  to  provide
Wake  Forest  University  Baptist Medical  Center  with  the
ThermoChem-HT  System  and disposable  ThermoChem-HT  System
packs   for  all  intraperitoneal  hyperthermia  procedures.
ViaCirQ will realize significant revenue from this contract,
although the exact amount is not known at this time.
       Intraperitoneal hyperthermia is used as an adjunctive
therapy with surgery and chemotherapy to treat patients with
peritoneal carcinomatosis (advanced cancer of the  abdomen).
This  treatment is extending life for many who have few,  if
any, options remaining.
     ViaCirQ received FDA clearance to market the ThermoChem-
HT  System  to  raise the core temperature of the  abdominal
cavity  to  the  desired  targeted temperature  in  the  41C
(105.8F) to 42C (107.6F) range by continuously lavaging  the
abdomen  with  circulating sterile  solution.  Studies  have
shown that heating of the abdominal cavity can make the area
more  receptive  to  adjunctive therapies  physicians  might
choose, such as chemotherapy.
     The  treatment was developed clinically by Wake  Forest
University  Baptist Medical Center and is now offered  as  a
standard-of-care  for  treating advanced  abdominal  cancer.
Five-year data shows patients undergoing this treatment live
longer and have a better quality of life.
     A major research center, Wake Forest University Baptist
Medical  Center  provides many of the latest  treatments  to
patients  and leads the way in researching new and promising
therapies   of  tomorrow.   The  ThermoChem-HT   System   is
manufactured by Biocontrol Technology, Inc., a BICO division
which   is  an  FDA  registered  manufacturer  and  an   ISO
9001/EN46001  certified manufacturing  facility  located  in
Indiana, PA.
     BICO, Inc. has its corporate offices in Pittsburgh,  PA
and  is  involved  in  the development  and  manufacture  of
biomedical  devices  and  environmental  products.    BICO's
subsidiary,  ViaCirQ, Inc., also located in Pittsburgh,  PA,
holds exclusive worldwide marketing rights to the ThermoChem-
HT  System and related disposables for regional hyperthermia
and  the ThermoChem System and related disposables for whole
body hyperthermia.





FOR FURTHER INFORMATION, CONTACT:
Investors                                  Media
Diane McQuaide                             Susan Taylor
1.412.429.0673 phone                       1.412.429.0673 phone
1.412.279.9690 fax                         1.412.279.5041 fax


INVESTOR RELATIONS NEWSLINE NUMBER:  1.800.357.6204
WEBSITE:  www.bico.com















© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission